
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc has shown a promising increase in grant revenue, rising to $4.4 million in 2023, indicating strong support for its Rhenium (186Re) Obisbemeda development from CPRIT. The preliminary results from the clinical trials reveal a favorable progression and survival signal for their lead candidate, suggesting a meaningful therapeutic benefit that could enhance patient outcomes beyond typical expectations. Additionally, the advancement of CNSide’s CSF assay platform positions Plus Therapeutics strategically to optimize clinical decision-making and reinforce its leadership in the development of innovative therapies within CNS oncology.
Bears say
Plus Therapeutics Inc. reported a significant decrease in cash and investments, falling from $8.6 million at the end of 2023 to $4.8 million in the third quarter of 2024, raising concerns about its financial stability and ability to fund ongoing clinical development. The company faces substantial challenges within the central nervous system cancer treatment landscape, where existing therapies struggle with efficacy and tolerability, compounded by the heterogeneity of tumors and their propensity for rapid treatment resistance. Furthermore, the risk factors outlined, including potential failures in clinical trials, regulatory approval, and financial viability due to competition and changing economic conditions, contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares